ProMIS Neurosciences to Present at Rodman & Renshaw 18th Annual Global Investment Conference

TSX: PMN

TORONTO, Sept. 12, 2016 /CNW/ - ProMIS Neurosciences, Inc. ("ProMIS" or the "Company") today announced that the company will present at the 18^th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The conference is being held September 11-13, 2016, at Lotte New York Palace Hotel in New York City.

Gene Williams, Executive Chairman of ProMIS, will provide a corporate overview and review product portfolio progress and development plans during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

The presentation will be webcast live and can be accessed through the Company's website at www.promisneurosciences.com, and a replay will be available on the website for 90 days.

Presentation Time
September 13, 2016
2:10 PM (Eastern Time)
Location: Kennedy I (4 th Floor), Lotte New York Palace Hotel

About ProMIS Neurosciences, Inc.

The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for the effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS.

ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences aims to develop novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please consult the Company's website at:
www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

SOURCE ProMIS Neurosciences Inc.

NATIONAL Equicom: Michael Moore: 858-886-7813, [email protected], Abby Garfunkel: 403-218-2887, [email protected] or contact Dr. Elliot Goldstein, President and Chief Executive Officer, ProMIS Neurosciences Inc., Tel. [phone], [email protected]